Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Takafumi Mukaihira"'
Autor:
Fumihiko Saitoh, Hidemitsu Nishida, Yoshitaka Hosaka, Munetaka Ohkouchi, Naoto Kosuga, Ikuya Shiromizu, Tomokazu Matsusue, Ichiro Yamamoto, Miwa Matsumoto, Takafumi Mukaihira
Publikováno v:
Chemical and Pharmaceutical Bulletin. 55:317-323
In the course of development of factor Xa (FXa) inhibitors, we have found unique compounds containing an N,O- and an N,N-spiro acetal structure. It appeared that the difference in overall conformation due to the N,X-spiro acetal structure might be im
Publikováno v:
European Journal of Organic Chemistry. 2006:5454-5457
The first asymmetric syntheses of antithrombotic agents M58163 and M58169 are reported. Dynamic kinetic resolution is observed in the amide formation step. (© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2006)
Publikováno v:
Eur. J. Org. Chem.. 2006(No. 10):2269-2272
The first asymmetric synthesis of antithrombotic agent M55529 is reported, wherein the first enantioselective cyclic N,O-acetal formation is clarified. (© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2006)
Autor:
Fumihiko Saitoh, Hidenori Mochizuki, Atsushi Okamoto, Hidemitsu Nishida, Yoshitaka Hosaka, Hiroyasu Shimada, Tomokazu Matsusue, Yutaka Miyazaki, Takafumi Mukaihira, Kazuhiro Suzuki, Masashi Mizuno, Miwa Matsumoto, Shuhei Ohnishi
Publikováno v:
Chemical and Pharmaceutical Bulletin. 52:459-462
Compounds containing an ethylenediamine structure in place of the piperazine ring of M55113 (1) and M55551 (2) were synthesized to investigate the effects of a piperazine moiety and evaluated for activity as factor Xa (FXa) inhibitors. Most such comp
Autor:
Hidemitsu Nishida, Yoshitaka Hosaka, Harada Kousuke, Manabu Itoh, Aki Muraoka, Hidenori Mochizuki, Tomokazu Matsusue, Fumihiko Saitoh, Miwa Matsumoto, Miyuki Fukui, Shuhei Ohnishi, Atsushi Okamoto, Takafumi Mukaihira, Yutaka Miyazaki
Publikováno v:
Chemical and Pharmaceutical Bulletin. 50:1187-1194
Intravascular clot formation is an important event in a number of cardiovascular diseases. The prevention of blood coagulation has become a major target for new therapeutic agents. Factor Xa (FXa) is a trypsin-like serine protease that plays a key ro
Publikováno v:
Chemical and Pharmaceutical Bulletin. 42:1784-1790
Chiral syntheses of 3-methyl-5-(phenylthio)-L-histidine (8a) and 3-methyl-5-(1-naphthalenylthio)-L-histidine (8b), selected as models for the asteroid alkaloid imbricatine (7), have been accomplished through a 10-step route starting from 4(5)-bromoim
Publikováno v:
ChemInform. 26
Chiral syntheses of 3-methyl-5-(phenylthio)-L-histidine (8a) and 3-methyl-5-(1-naphthalenylthio)-L-histidine (8b), selected as models for the asteroid alkaloid imbricatine (7), have been accomplished through a 10-step route starting from 4(5)-bromoim
Autor:
Hidemitsu Nishida, Fumihiko Saitoh, Ichiro Yamamoto, Takafumi Mukaihira, Naoto Kosuga, Miwa Matsumoto, Yoshitaka Hosaka, Munetaka Ohkouchi, Ikuya Shiromizu, Tomokazu Matsusue
Publikováno v:
ChemInform. 38
Autor:
Fumihiko, Saitoh, Hidemitsu, Nishida, Takafumi, Mukaihira, Naoto, Kosuga, Munetaka, Ohkouchi, Tomokazu, Matsusue, Ikuya, Shiromizu, Yoshitaka, Hosaka, Miwa, Matsumoto, Ichiro, Yamamoto
Publikováno v:
Chemicalpharmaceutical bulletin. 55(2)
In the course of development of factor Xa (FXa) inhibitors, we have found unique compounds containing an N,O- and an N,N-spiro acetal structure. It appeared that the difference in overall conformation due to the N,X-spiro acetal structure might be im
Publikováno v:
Adv. Synth. Cat.. 349
Dynamic kinetic resolution is one of the most synthetically useful phenomena for asymmetric synthesis. Dynamic kinetic resolution for the catalytic asymmetric synthesis of a spiro[imidazo[1,2-a]pyrazine-2(3H),4′-piperidin]-5(1 H)-one scaffold with